Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study
Overlooked Treatments
Azvudine versus Paxlovid in COVID‐19: A systematic review and meta‐analysis
Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients - BMC Infectious Diseases
Research shows how HIV drug could stop many coronavirus diseases
Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment
Efficacy and safety of azvudine in patients with COVID-19: A systematic review and meta-analysis
Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study
Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities
Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study - BMC Infectious Diseases
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
Murphy's Medicine Podcast: Episode One. SARS CoV2 Associated Neurocognitive Decline
SARS-Cov-2 Associated Neurocognitive Decline (SAND) Scan
Study Shows How Paxlovid Resistance Emerges in Persistent Infections
“This type of approach helped to improve HIV drugs, and we think it’s a good way to improve antivirals against SARS-CoV-2,” says Sho Iketani, PhD, assistant professor of medical sciences at Columbia University’s Vagelos College of Physicians and Surgeons and Aaron Diamond AIDS Research Center, who co-led the research with David D. Ho, MD, the Clyde '56 and Helen Wu Professor of Medicine, professor of microbiology & immunology, and director of the Aaron Diamond AIDS Research Center, and Haitao Yang, PhD, of ShanghaiTech University.
How monoclonal antibodies lost the fight with new COVID variants